Four new SPMS patients not eligible for a Tiziana Life Sciences trial were dosed with foralumab nasal spray in an expanded access program.

Explore key insights from ICON's Q4 2024 earnings call, including bookings growth, digital innovation, and strategic partnerships driving 2025 growth targets.

The registrational trial will include 212 patients who are newly diagnosed with advanced head and neck cancer.

Based on alignment gained with FDA under the Regenerative Medicine Advanced Therapy (RMAT) designation, Neurona plans to conduct the Phase 3 ...

She faces 5-99 years in prison for injury to a child by omission if the Texas Attorney General's Office gets its way during ...

Assembly Biosciences (ASMB) announced promising interim results from its ongoing Phase 1a/b study of ABI-1179, an investigational drug which is a long-acting helicase-primase inhibitor for recurrent ...

People with Duchenne or Becker muscular dystrophy who had more siblings typically report being better prepared to transition to adult life, a study says.

OXB announces that its proprietary lentiviral vector manufacturing technology will be used in Boehringer Ingelheim’s newly initiated LENTICLAIR ...

Sensorion (FR0012596468 ? ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today ...